- Partnering with the leading HIV research centres, Gilead established the Young Emerging Scientists (YES) HIV Fellowship program to inspire the next generation of Australian scientists.
- The YES HIV Fellowship program was designed to support passionate undergraduate or masters students looking to make HIV science their area of focus.
- Four rising science students from across Australia have now completed the inaugural three-month fellowship at some of Australia’s top HIV research centres.
Melbourne, Australia, December 1, 2023 – Gilead Sciences Australia announced today, to mark World AIDS Day the first cohort’s completion of the Young Emerging Scientists (YES) 2023 HIV Fellowship program, a new initiative aimed at developing the next generation of Australian HIV scientists.
The YES HIV 2023 Fellowship was established by Gilead in collaboration with mentors from Australia’s preeminent HIV research centres including the Burnet Institute (Melbourne), the Kirby Institute (Sydney), the Peter Doherty Institute for Infection and Immunity (Melbourne) and the Centre for Social Research in Health, UNSW (Sydney) to inspire the next generation of scientists to continue the pursuit to eliminating HIV as a public health threat.
After a two-month search and almost 50 applications from students across Australia, the mentors selected four outstanding recipients with exceptional academic excellence, a demonstrated passion for the HIV sciences and a genuine commitment to contributing to HIV research and its potential impact on society.
The awarded recipients of the YES HIV 2023 Fellowships were:
- Mia Cahill - undertaking a Bachelor of Medical Science, University of Notre Dame
- Lalu Faris Naufal Makhroja - undertaking a Masters of Public Health, University of Melbourne
- Hailey Cheng - undertaking a Bachelor of Biomedical Science, Monash University
- Mehran Mejbah- undertaking a Bachelor of Biomedical Science, Monash University.
The Fellows experienced firsthand the diverse and innovative work currently underway in HIV sciences in Australia, spending immersion days at each of the four sites, giving them an opportunity to interact with some of the most distinguished national and international HIV researchers based at these sites.
Fellows were also supported by Gilead to attend the International AIDS Society (IAS) Conference in Brisbane in July, providing an unparalleled opportunity for the students to network with Australian and global leaders in the HIV community, exchange ideas and gain further exposure to the latest international advancements and breakthroughs in HIV science and research.
“While Australia’s response to the HIV epidemic has been world-leading over the last four decades, and the local HIV community has made incredible strides with respect to prevention, treatment, care and advocacy, it is critical we do not lose momentum especially now as ending HIV transmission is within reach. This is particularly important as we are starting to see a generational change in this space, and we need to ensure all that incredible knowledge, science and experience is passed on to the next vanguard of cutting-edge clinicians and scientists,” said Dr Paul Slade, Senior Country Medical Director, Gilead Australia and New Zealand.
“This World AIDS Day marks the 35th year of the first-ever international day for global health, and we know the success of the HIV response in Australia is through the partnership and collaborations that exist between people living with HIV, advocates, healthcare professionals, researchers, industry and governments. We are very proud to support the next generation of talent in HIV sciences and with the exceptional calibre of students involved in this first year, we are filled with great confidence in the future of ongoing HIV research and clinical practice in Australia,” said Dr Paul Slade.
Brent Allan, Global Community Engagement Consultant, who was engaged by Gilead to project manage the YES HIV Fellowship program commented: “It has been immensely gratifying for us to be able to facilitate this opportunity and watch the students absorb, critically question and interact with scholars, clinicians, patient advocates and people living with HIV. It’s our hope this experience has now further encouraged and inspired the Fellows to see what is possible, pursue the HIV sciences and take the baton in ending the HIV epidemic for all. We are excited to witness the growth and impact of these exceptional students as they continue their studies.”
To view videos of YES HIV 2023 Fellowship recipients Faris and Hailey, please click here.
- ENDS –
For medical information enquiries or to report an adverse event, please contact Gilead on 1800 806 112 (within Australia) or email au.nz.medinfo@gilead.com.
Issued by SenateSHJ on behalf of Gilead Sciences.
Note to Editors:
About YES
The Young Emerging Scientist (YES) 2023 HIV Fellowships were open to Australian residents over the age of 18 years who are undergraduates who have not yet begun their honours or masters, or students who have not yet completed the major research component of their studies. These fellowships are intended to introduce the recipients to the diversity of work currently being done across the HIV sciences in Australia.
With a long history in working with and supporting local research centres and organisations to advance efforts to end the HIV epidemic, Gilead introduced the YES HIV Fellowships earlier this year, specifically to encourage the next generation of scientists build on the great strides already made by world-leading Australian scientists in the HIV sciences.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Based in Melbourne, Gilead Sciences Australia and New Zealand employs over 100 people.
Gilead, the Gilead logo and the Creating Possible tagline are registered trademarks of Gilead Sciences, Inc. Gilead Sciences Pty Ltd. Level 28, 385 Bourke Street, Melbourne VIC 3000, Victoria, Australia. ABN 71 072 611 708. AU-UNB-0760. Date of preparation: November 2023.
References:
- IAS 2023 Programme. Progress towards HIV elimination: Are we there yet? Australia’s progress towards ending HIV as a public health threat: trends in epidemiological metrics over 2004-2021. Available at: https://programme.ias2023.org/Programme/Session/4409. Accessed 20 September 2023.
- IAS 2023 Media Release: https://www.iasociety.org/news-release/hiv-transmission-virtually-eliminated-inner-sydney-australia. Accessed 20 September 2023.
- UNAIDS. World AIDS Day. Available at https://www.unaids.org/en/World_AIDS_Day. Accessed 20 September 2023.
Contact details:
Susannah Wade +61 477 000 682
